AJCC |
American Joint Committee on Cancer |
AP-1 |
Activator protein-1 |
BDNF |
Brain-derived neurotrophic factor |
CI |
Confidence interval |
cN |
Clinical nodal |
CT |
Computed tomography |
DNA |
Deoxyribonucleic acid |
DOI |
Depth of invasion |
EGFR |
Epidermal growth factor receptors |
EMT |
Epithelial to mesenchymal transition |
ENE |
Extracapsular nodal extension |
ERK |
Extracellular-regulated protein kinase |
FDA |
Food and Drug Administration |
FGFR |
Fibroblast growth factor receptor |
GALR |
Galanin receptor |
GDNF |
Glial cell-derived neurotrophic factor |
GFAP |
Glial fibrillary acidic protein |
GFRalpha1 |
GDNF family receptor-alpha 1 |
HPV |
Human papilloma virus |
HR |
Hazard ratio |
IMRT |
Intensity-modulated radiation therapy |
LOH |
Loss of heterozygosity |
M |
Metastasis |
MAPK |
Mitogen-activated protein kinase |
MMP |
Matrix metalloproteinase |
MR |
Magnetic resonance |
mRNA |
Messenger ribonucleic acid |
NCAM |
Neural cell adhesion molecule |
NFATC |
Nuclear factor of activated T cells |
NGF |
Nerve growth factor |
OR |
Odds ratio |
p75NTR |
p75 neurotrophin receptors |
PD-L1 |
Programed cell death -ligand 1 |
pN |
Pathological nodal |
PNI |
Perineural invasion |
RET |
REarranged during Transfection |
SCC |
Squamous cell carcinoma |
shRNA |
Short hairpin ribonucleic acid |
T |
Tumor |
TNF |
Tumor necrosis factor |
TrkA |
Tropomyosin receptor kinase A |
TrkB |
Tropomyosin receptor kinase B |